Levetiracetam for Managing Neurologic and Psychiatric Disorders

Muhammad U. Farooq; Archit Bhatt; Arshad Majid; Rishi Gupta; Atul Khasnis; Mounzer Y. Kassab


Am J Health Syst Pharm. 2009;66(6):541-561. 

In This Article

Drug Interactions

In vitro data on metabolic interactions indicate that oral and i.v. levetiracetam are unlikely to produce or be subject to pharmacokinetic interactions.[16,107] Levetiracetam and its major metabolite (at concentrations well above concentration maximum levels achieved within the therapeutic dose range) are neither inhibitors of nor high affinity substrates for human liver CYP isoforms, epoxide hydrolase, or uridine diphosphate glucuronidation enzymes. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.

It is safe to give oral and i.v. levetiracetam to patients who are taking warfarin, digoxin, oral contraceptives, and other AEDs, including phenytoin, and valproic acid.[15] However, levetiracetam may increase the effects of other drugs that cause drowsiness, including antidepressants, alcohol, antihistamines, and sedatives.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.